|246.14||+2.74||+1.13%||Vol 136.89K||1Y Perf 35.22%|
|Jun 24th, 2021 11:35 DELAYED|
|- -%||- -|
|Target Price||221.00||Analyst Rating||Hold 2.67|
|Potential %||-10.13||Finscreener Ranking||★ 39.66|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★ 42.26|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★ 60.17|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||★+ 35.42|
|Market Cap||35.82B||Earnings Rating||Sell|
|Price Range Ratio 52W %||99.19||Earnings Date||4th Aug 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th Aug 2021|
|Estimated EPS Next Report||1.28|
|EPS Growth Next 5 Years %||13.90|
|Avg. Weekly Volume||579.65K|
|Avg. Monthly Volume||680.19K|
|Avg. Quarterly Volume||616.37K|
ResMed Inc. (NYSE: RMD) stock closed at 243.4 per share at the end of the most recent trading day (a 0.96% change compared to the prior day closing price) with a volume of 567.01K shares and market capitalization of 35.82B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 7770 people. ResMed Inc. CEO is Michael J. Farrell.
The one-year performance of ResMed Inc. stock is 35.22%, while year-to-date (YTD) performance is 14.51%. RMD stock has a five-year performance of 304.07%. Its 52-week range is between 165.72 and 246.8, which gives RMD stock a 52-week price range ratio of 99.19%
ResMed Inc. currently has a PE ratio of 75.90, a price-to-book (PB) ratio of 12.75, a price-to-sale (PS) ratio of 11.28, a price to cashflow ratio of 41.30, a PEG ratio of 2.32, a ROA of 8.98%, a ROC of 12.90% and a ROE of 16.60%. The company’s profit margin is 14.54%, its EBITDA margin is 34.80%, and its revenue ttm is $3.09 Billion , which makes it $21.24 revenue per share.
Of the last four earnings reports from ResMed Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.28 for the next earnings report. ResMed Inc.’s next earnings report date is 04th Aug 2021.
The consensus rating of Wall Street analysts for ResMed Inc. is Hold (2.67), with a target price of $221, which is -10.13% compared to the current price. The earnings rating for ResMed Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ResMed Inc. has a dividend yield of 0.65% with a dividend per share of $1.56 and a payout ratio of 32.00%.
ResMed Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 15.37, ATR14 : 4.98, CCI20 : 112.95, Chaikin Money Flow : 0.13, MACD : 10.81, Money Flow Index : 82.82, ROC : 17.76, RSI : 80.51, STOCH (14,3) : 95.63, STOCH RSI : 0.54, UO : 68.24, Williams %R : -4.37), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ResMed Inc. in the last 12-months were: Brett A. Sandercock (Sold 32 500 shares of value $6 430 450 ), Brett Sandercock (Sold 2 500 shares of value $492 450 ), David B. Pendarvis (Sold 0 shares of value $-1 809 286 ), David B. Pendarvis (Sold 40 003 shares of value $7 694 236 ), James R. Hollingshead (Sold 28 800 shares of value $5 695 154 ), Justin Leong (Sold 0 shares of value $-447 062 ), Justin Leong (Sold 7 740 shares of value $1 635 926 ), Rajwant Sodhi (Sold 16 500 shares of value $3 217 485 ), Robert Andrew Douglas (Sold 0 shares of value $-931 840 ), Robert Andrew Douglas (Sold 26 336 shares of value $5 423 264 ), Ronald R. Taylor (Sold 4 000 shares of value $800 564 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.